The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The role of surgical resection following imatinib treatment in patients with metastatic or recurrent GIST.
Baek-Yeol Ryoo
No relevant relationships to disclose
Seong Joon Park
No relevant relationships to disclose
Min-Hee Ryu
No relevant relationships to disclose
Byeong Seok Sohn
No relevant relationships to disclose
Hwa Jung Kim
No relevant relationships to disclose
Ki-Hun Kim
No relevant relationships to disclose
Sung Tae Oh
No relevant relationships to disclose
Chang Sik Yu
No relevant relationships to disclose
Jeong Hwan Yook
No relevant relationships to disclose
Byung Sik Kim
No relevant relationships to disclose
Yoon-Koo Kang
Consultant or Advisory Role - Bayer; Novartis
Honoraria - Novartis
Research Funding - Bayer; Novartis